Israel - Arab - Ministry of Health

teva pharmaceutical indust.ltd - alfacalcidol 0.25 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

Israel - Arab - Ministry of Health

teva pharmaceutical indust.ltd - alfacalcidol 1 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

Israel - Arab - Ministry of Health

teva pharmaceutical indust.ltd - atenolol 100 mg - tablets - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

Israel - Arab - Ministry of Health

abic ltd. - atenolol 50 mg - tablets - atenolol - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction

Israel - Arab - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg - tablets - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

Israel - Arab - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 10 mg - tablets - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

Israel - Arab - Ministry of Health

sanofi - aventis israel ltd - hydrochlorothiazide 12.5 mg; ramipril 2.5 mg - tablets - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Israel - Arab - Ministry of Health

dexcel pharma technologies ltd - losartan potassium 50 mg - tablets - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

Israel - Arab - Ministry of Health

bayer israel ltd - drospirenone 3 mg; ethinylestradiol 0.03 mg - film coated tablets - drospirenone and estrogen - oral contraception.

Israel - Arab - Ministry of Health

bayer israel ltd - drospirenone 3 mg; ethinylestradiol 0.02 mg - film coated tablets - drospirenone and estrogen - - oral contraception. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms ( premenstrual syndrome ).